Indication
As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy.
Medicine details
- Medicine name:
- ivosidenib (Tibsovo)
- SMC ID:
- SMC2664
- Pharmaceutical company
- Servier Laboratories Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 09 September 2024
- SMC meeting date:
- 06 August 2024
- Patient group submission deadline:
- 03 June 2024